Jaunts Across the Border Best Rx for High Drug Prices?


Treks into Canada or Mexico to buy cheap prescription drugs have long been the norm for many U.S. citizens. However, during the 2000 campaign season new faces have been showing up for these rides: Political candidates.

In at least 11 states (Maine, Michigan, Minnesota, Montana, Nevada, New York, North Dakota, Ohio, Pennsylvania, Vermont and Washington) incumbents and hopefuls have chartered buses for seniors, and in some cases gone along as a group sets off for a Canadian or Mexican destination.

Independent U.S. Rep. Bernie Sanders from Vermont and Democratic Montana rancher Brian Schweitzer, who is trying to unseat Republican U.S. Sen. Conrad Burns, are considered to be at the forefront of this movement.

They've been pointing seniors toward drug-buying trips since 1999. Schweitzer alone has taken three bus trips to Canada and one trip by plane to Mexico.

Republican Vermont U.S. Sen. James Jeffords and Democratic New York Rep. Joseph Crowley have also played an active role in helping U.S. citizens get cheaper prescription drugs abroad, according to the AARP advocacy group.

The excursions usually work like this: A busload of seniors journey to Canada with prescriptions written by American doctors. Once across the border a Canadian doctor will rewrite the prescription, then take it to a Canadian pharmacy to be filled with drugs costing a fraction of their U.S. price.

For example, Tamoxifen, a drug used to treat breast cancer, typically costs about $110 for a one-month supply in Maine. In Canada, a month's worth of Tamoxifen is about $12, or about one-tenth of the U.S. cost.

Every six weeks or so, two vans containing about 10 people apiece set out from Montpelier, Vermont, for a two and a half-hour ride to Montreal, Canada, courtesy of the Central Vermont Council on Aging (CVCOA). Vermont Rep. Sanders got the excursions under way, says CVCOA spokesman Will Fleming, adding that residents of the richest country on earth shouldn't have to go to neighboring countries for affordable drugs.

"It shows how we kind of don't take care of our weak links in society," Fleming says. "The school of thought seems to be: `Those who can afford it, fine -- those who can't, well, it's not our problem.'"

Fleming couldn't name a Vermont state politician currently helping state residents to get cheap drugs from Canada. Nor could Montpelier dairy farmer Ramona Christensen, 46, who recently caught a CVCOA van to Montreal to buy nine prescription drugs, saving herself $1,600 on three month's worth of pharmaceuticals.

"I would like them (state legislators) to lose everything they have, live on $1,000 a month, be ridden with five serious diseases and not be able to get state help," says Christensen, who suffers from diabetes and a stomach disorder, among other ailments. "In a year's time of living like that, I'd like to see what they would do."

According to a Congressional Research Service study, on average Vermont seniors pay 81 percent more than Canadians for the 10 most widely used prescription drugs.

In Maine, state politicians passed a law four months ago that established a commission that can negotiate drug prices for uninsured Maine residents, WebMD Medical News reported. A similar Vermont bill seeking drug price caps was defeated following "the most intensive lobbying effort" state House Speaker Michael Obuchowski recalled seeing in 28 years, WebMD Medical News wrote.

While the drug-buying bus trips prove that pharmaceuticals cost less elsewhere, it remains to be seen whether the involvement of political candidates will drive public policy or merely be viewed as a campaign tactic.

"It's by no means a solution," says Amanda McCloskey, director of health policy analysis at Families USA, a liberal patient-advocacy group. "But I really do think [the bus trips] illustrate just how bad the problem is, and quite frankly, how ridiculous it is that pharmaceutical manufacturers are willing to give other countries a lower price and we basically are paying the highest price possible."

Pharmaceutical Research and Manufacturers Of America (PHRMA), a trade group that represents drug makers, says that the bus trips do not tell the whole story.

"We don't need to import into the United States Canada's price controls. Price controls clearly stifle innovation," said Jeff Trewhitt, a spokesman for PHRMA.

Trewhitt says that although Americans pay more for their drugs, new drugs are available to them at an average of a year earlier than they are to Canadians.

Various plans are afoot that would add a prescription drug benefit to Medicare, but with time running out before Congress goes out of session change isn't expected this year. There is also drug price-relief legislation pending that would make it easier to import U.S.-made drugs from overseas, where they cost less.

While Schweitzer conceded that the bus trips have helped his campaign, he adds that the re-importation legislation resulted from the publicity the trips generated.

Senior Writer Blair S. Walker contributed to this article.


Related Stories

    • Stateline Story
    January 15, 2014
    States Air Their Differences at Supreme Court image description

    In the Supreme Court’s spring 2014 term, a familiar cast will be airing arguments and hashing out their differences before the justices state attorneys general. States are increasingly weighing in on disputes that end up before the Supreme Court. A


    • Stateline Story
    February 24, 2012
    image description

    TODAY'S TAKE: Seven Republican attorneys general are suing the Obama administration over a rule requiring religious-affiliated organizations to make birth control coverage available for employees. more

    • Stateline Story
    January 31, 2008
    image description

    President Bush said in his State of the Union address Jan. 28 that groundbreaking new stem-cell research that uses ordinary skin cells instead of human embryos "has the potential to move us beyond the divisive debates of the past."  But far from resolving the moral quandary, last November's highly publicized scientific breakthrough has escalated the discussion. Stateline.org outlines the states' pivotal role in this international issue in a special "Backgrounder" that details state and federal stem cell policies and politics, economic opportunities presented by the science and the history of the ethical debate.

    • Stateline Story
    January 15, 2008
    image description

    As the pace of stem-cell research quickens, seven big states are financing the science in hopes of attracting the world's best scientists to lead what many predict will be a multi-billion-dollar bioscience bonanza. But not all states are headed in the same direction. See what's at stake in this excerpt from "State of the States 2008," Stateline.org's forthcoming annual report on significant state policy developments and trends.

    • Stateline Story
    June 21, 2007
    image description

    President Bush's second veto of a bill to allow federal funding of stem cell research puts the ethical issue squarely in states' hands. So far, seven states have moved to fund the research, six have banned it, three have affirmed its legality but do not fund it and a handful of others continue to debate the issue.